탭메뉴
| 번호 | 구분 | 제목 |
|---|---|---|
| 303 | (국외)SCI | High levels of baseline serum IL-10 are associated withreduced clinical benefit from first-line immunecheckpoint inhibitor therapy in advanced renal cellcarcinoma |
| 302 | (국외)SCIE | High Serum Levels of IL-6 Predict Poor Responses in Patients Treated with Pembrolizumab plus Axitinib for Advanced Renal Cell Carcinoma |
| 301 | (국외)SCIE | Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab |
| 300 | (국외)SCIE | Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population |
| 299 | (국외)SCIE | Risk of Variceal Bleeding in Patients With Advanced Hepatocellular Carcinoma Receiving Atezolizumab/Q1 Bevacizumab |
| 298 | (국외)SCIE | Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study |
| 297 | (국외)SCIE | Predictive biomarkers of survival in patients with advanced hepatocellular carcinoma receiving atezolizumab plus bevacizumab treatment |
| 296 | (국외)SCIE | Association of High Levels of Antidrug Antibodies Against Atezolizumab With Clinical Outcomes and T-Cell Responses in Patients With Hepatocellular Carcinoma |
| 295 | (국외)SCI | Prognostic implication of serum alpha-fetoprotein in patients with hepatocellular carcinoma treated with regorafenib |
| 294 | (국외)SCIE | Could We Predict the Response of Immune Checkpoint Inhibitor Treatment in Hepatocellular Carcinoma? |
Copyright ⓒ chamc, All rights reserved.
